Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors
Nektar Therapeutics (NKTR) today announced that it has initiated dosing patients in the Phase 1/2 REVEAL clinical study evaluating the efficacy and safety of the combination of investigational medicines NKTR-262 and NKTR-214 in the treatment of solid tumors. NKTR-262 is a novel toll-like receptor (TLR) agonist designed to induce the body’s innate immune response and create antigen-specific T cells to fight cancer. NKTR-214 is designed to activate the adaptive immune system to expand and proliferate these specific cancer-fighting T cells in the tumor micro-environment.
…
NKTR-262 is a novel small molecule agonist designed to activate toll-like receptors (TLRs). Intratumoral delivery of NKTR-262 promotes TLR activation to induce the development of antigen-specific immunity by initiating the process by which the immune system generates antigen-specific cytotoxic T cells to the patient’s specific tumor.2 NKTR-214 targets CD122 specific receptors found on the surface of these cancer-killing immune cells, known as CD8+ effector T cells. By first generating antigen-specific cytotoxic T cells with NKTR-262 and then growing these CD8+ effector T cells with NKTR-214, the patient’s entire immunity cycle can potentially be engaged to fight cancer.
Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors
Wow, this is the initiation of what may be one of the most important treatment studies of our lifetime, and I’m the only one who gave a rec to this post by Dominic. Are you guys asleep?
Saul
No not sleeping Saul, but I was working out on the farm. LOL Horses are fed, chickens are watered and the planting is done for now in the garden and this post is, hopefully, great news for the future.
Mike
We knew that this study was going to be started at or near the end of March because it was reported during the last earnings call. I will get a little excited if the results look promising. But we should all remember that the trial just started and that this is a Phase I/II trial.
We knew that this study was going to be started at or near the end of March because it was reported during the last earnings call. I will get a little excited if the results look promising. But we should all remember that the trial just started and that this is a Phase I/II trial.
With the number of people we have on this board, I wonder if there might end up being any connections from which anyone might know any patients that will be part of the study?
“The primary objectives are safety, tolerability and objective response rate through study completion (~two years). According to ClinicalTrials.gov, the estimated primary completion date is November 2019.”
…the estimated primary completion date is November 2019.
Yes, I saw that, as I’ve never followed one of these trials before, I guess I was wondering if it’s typical that there are any preliminary announcements of early results ahead of this date?
